Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics
(PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be
performed on all subjects. The eligible subject population consists of subjects who have been
diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy
or for which no curative standard therapy exists.